Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | TGM2 | P21980 | 5/20 | 0.47 |
| ▸ | F13A1 | P00488 | 4/20 | 0.46 |
| ▸ | TGM1 | P22735 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27056253 | 0.89 | KDM4E (0.60) | KDM4EPKMTGM2F13A1TGM1 | |
| SCHEMBL4012248 | 0.83 | KDM4E (0.53) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL16014055 | 0.83 | KDM4E (0.53) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL3256049 | 0.82 | EPHX1 (0.48) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL4426117 | 0.80 | KDM4E (0.55) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL16099475 | 0.80 | ACHE (0.41) | TGM2 | |
| SCHEMBL9407985 | 0.80 | KDM4E (0.52) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL16224989 | 0.80 | GPR119 (0.53) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL12965743 | 0.80 | KDM4E (0.50) | KDM4EPKMGPR119EPHX1HPGD | |
| SCHEMBL3056140 | 0.80 | GPR119 (0.50) | KDM4EPKMGPR119EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 1936/4885PKM 4158/4885GPR119 3888/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 1936/4885PKM 4158/4885GPR119 3888/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 1936/4885PKM 4158/4885GPR119 3888/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | KDM4E 1936/4885PKM 4158/4885GPR119 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.